<DOC>
	<DOCNO>NCT02006667</DOCNO>
	<brief_summary>This study evaluate efficacy safety chemotherapy regimen intravenous Herceptin , cisplatin gemcitabine patient metastatic urothelial cancer . The anticipated time study treatment disease progression .</brief_summary>
	<brief_title>A Study Herceptin ( Trastuzumab ) Combination Therapy Patients With Metastatic Urothelial Cancer</brief_title>
	<detailed_description />
	<mesh_term>Urologic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>adult patient &gt; =18 year age ; metastatic urothelial carcinoma ; measurable metastasis local recurrent disease ; prior chemotherapy metastatic disease ; HER2 overexpression ( IHC [ 2+ ] [ 3+ ] ) . concomitant chemotherapy immunotherapy ; active uncontrolled infection ; solely CNS metastasis ; clinically significant cardiac disease , advance pulmonary disease severe dyspnoea ; coexist malignancy diagnose within last 5 year , except basal cell cancer cervical cancer situ .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>